Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Genpact Ltd President and CEO Balkrishan Kalra reported a tax‑withholding transaction involving 29,691 common shares. On 01/10/2026, 29,691 Genpact common shares were withheld at a price of $48.24 per share to pay taxes due upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan, in a transaction coded "F" and exempt under Rule 16b-3.
After this withholding, Kalra directly holds 390,685 common shares of Genpact. This event reflects shares being retained by the company for tax purposes rather than an open-market sale.
Genpact Ltd senior vice president Sameer Dewan reported two transactions in Genpact common shares. On January 10, 2026, 9,780 shares were withheld at $48.24 per share to cover taxes upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. After this withholding, Dewan beneficially owned 52,837 shares directly.
On January 13, 2026, Dewan sold 15,088 common shares at a weighted average price of $46.65 per share, with actual sale prices ranging from $46.40 to $47.05. These sales were made under a Rule 10b5-1 trading plan adopted on September 15, 2025. Following the sale, Dewan directly held 37,749 Genpact common shares.
Genpact Limited senior vice president Anil Nanduru reported a tax-related share withholding tied to equity compensation. On January 10, 2026, 11,871 common shares of Genpact Limited were withheld at a price of
After this transaction, Nanduru beneficially owned 77,975 common shares, held directly. The activity reflects routine tax withholding on vested stock awards rather than an open-market purchase or sale.
Genpact Limited senior vice president Riju Vashisht reported two transactions in the company’s common shares. On January 10, 2026, 10,733 shares were withheld to cover taxes upon vesting of restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan at a price of $48.24 per share. This was a tax-related withholding rather than an open-market sale.
On January 13, 2026, Vashisht sold 16,016 common shares at a weighted average price of $46.65 per share, with actual prices ranging from $46.40 to $47.05. These sales were executed under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025. After these transactions, Vashisht directly held 95,521 Genpact common shares.
Genpact LTD executive Piyush Mehta reported a routine tax-related share withholding. On 01/10/2026, 12,317 common shares were withheld at $48.24 per share to cover taxes due upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan, in a transaction exempt under Rule 16b-3.
After this transaction, Mehta directly beneficially owned 122,700 Genpact common shares. The filing also notes participation in the Genpact Employee Stock Purchase Plan, including 137 shares acquired since a prior Form 4, with a current total of 10,359 shares held under the ESPP.
Genpact Ltd’s Chief Financial Officer Michael Hal Weiner reported a routine tax-related share transaction. On January 10, 2026, 12,029 common shares were withheld at $48.24 per share to cover taxes due upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan, a transaction noted as exempt under Rule 16b-3. Following this withholding, Weiner beneficially owns 136,075 common shares directly. This total includes shares accumulated through the Genpact Employee Stock Purchase Plan, where he currently holds 1,436 shares, including 78 shares acquired since his prior Form 4 filed on November 17, 2025.
HEATHER D WHITE has filed a Form 144 notice to sell 10,740 shares of common stock of issuer G through Morgan Stanley Smith Barney LLC on or about 01/13/2026 on the NYSE. The planned sale has an aggregate market value of 500,964.08, compared with 172,414,423 shares of the same class reported as outstanding. The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026.
Over the prior three months, the same seller reported three sales of common stock, totaling 45,703, 4,351, and 1,039 shares, for gross proceeds of 2,090,455.22, 199,014.74, and 45,731.59, respectively. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
A holder of common shares of the issuer associated with symbol G has filed a Form 144 notice to sell 15,088 common shares through Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an indicated aggregate market value of $703,788.81, with 172,414,423 common shares reported as outstanding and an approximate sale date of 01/13/2026.
The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026, with the same date noted for payment and the nature of payment listed as not applicable. Over the past three months, the same seller, Sameer Dewan, sold 26,531 common shares for gross proceeds of $1,185,999.38, which is disclosed alongside the new planned sale.
A holder of common stock of G has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 16,016 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 01/13/2026. The aggregate market value of the shares listed for sale is $747,122.38, compared with 172,414,423 shares outstanding of the same class.
The shares to be sold were acquired as restricted stock from the issuer on 01/10/2026, with the consideration described as not applicable. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Genpact Limited reported that its SVP and Chief Legal Officer, Sydney Schaub, received an award of 63,357 common shares in the form of unvested restricted share units on 01/06/2026 at a grant price of $0 per share. Each RSU represents the right to receive one Genpact common share upon vesting. One-third of the shares underlying this RSU award will vest on each of December 8, 2026, December 8, 2027 and December 8, 2028, as long as Schaub continues in service through each vesting date. Following this grant, Schaub beneficially owned 63,357 common shares directly.